Centiva Capital’s Nektar Therapeutics NKTR Stock Holding History

Centiva Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-674	Closed	-$173K	–	1510
2021 Q2	$173K	Buy	+674	New	+$187K	﹤0.01%	1238

Other funds holding NKTR

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Centiva Capital's NKTR Position: Q3 2021 in Review

Centiva Capital sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 674 shares — an estimated $173K sold.

Centiva Capital first reported a position in NKTR in Q2 2021 and held it in 1 quarter. The position peaked at $173K in Q2 2021. 241 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

Centiva Capital reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
Centiva Capital sold 674 Nektar Therapeutics shares in Q3 2021, an estimated $173K.
Centiva Capital first reported a position in Nektar Therapeutics in Q2 2021 and held it in 1 quarter.
Centiva Capital's Nektar Therapeutics position peaked at $173K in Q2 2021.
241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.